Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 11/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12895734 | 0.81 | P2RX3 (0.54) | P2RX3MAPTGAAPOLBALDH1A1 | |
| SCHEMBL28806812 | 0.80 | KIF11 (0.41) | P2RX3RORCGLA | |
| SCHEMBL6524362 | 0.80 | KIF11 (0.41) | P2RX3RORCGLA | |
| Hydrochloric Acid SCHEMBL28806807 | 0.79 | KIF11 (0.40) | P2RX3RORCALDH1A1GLA | |
| Hydrochloric Acid SCHEMBL28806809 | 0.79 | KIF11 (0.40) | P2RX3RORCALDH1A1GLA | |
| SCHEMBL20969648 | 0.78 | P2RX3 (0.45) | P2RX3MAPTGAAALDH1A1KMT2A | |
| SCHEMBL12473138 | 0.78 | MAPK1 (0.53) | P2RX3MAPTGAAALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL31255681 | 0.77 | MAPK1 (0.51) | P2RX3MAPTGAAALDH1A1KMT2A | |
| SCHEMBL747450 | 0.74 | POLB (0.59) | MAPTGAAPOLBALDH1A1KMT2A | |
| SCHEMBL17707975 | 0.74 | ACHE (0.41) | P2RX3MAPTPOLBALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LIPE, PNLIP, LPL | P2RX3 876/4885MAPT 4639/4885GAA 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.